Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Midatech Pharma up 90% on Q-Sphera breakthrough

Thu, 17th Jun 2021 11:43

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Midatech Pharma PLC, up 89% at 51.90 pence, 12-month range 18.10p-87.00p. The biotechnology company says it has data demonstrating that its Q-Sphera technology can formulate monoclonal antibodies into long-acting injectables, a novel development in pharmaceuticals with significant medical and commercial potential. "The company believes no other commercial or academic organisation has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling," it says.

----------

Blue Prism Group PLC, up 7.4% at 964.50p, 12-month range 883.50p-1,900.00p. The robotic process automation firm posts narrowed interim loss after seeing growing revenue and booking numbers for the period. Blue Prism reports a pretax loss of GBP21.0 million for the six months ended April 30, sharply narrowed from GBP53.8 million a year prior. Bookings grew 35% in the first half to GBP98 million, or 39% at constant currency. Revenue for the period increased by 21% year-on-year to GBP80.4 million from GBP66.6 million, with recurring, subscription-based, licence revenue accounting for a 98% share.

----------

AIM - LOSERS

----------

Open Orphan PLC, down 14% at 30.00p, 12-month range 11.16p-34.50p. The pharmaceutical services company posts 2020 pretax loss GBP11.2 million, widened from GBP5.8 million on revenue from continuing operations of GBP20.6 million, up from GBP3.4 million. Separately, Poolbeg Pharma confirms plan to float on AIM as a spinoff of Open Orphan. Poolbeg Pharma to use IPO raise to fund clinical trial of treatment for severe influenza.

----------

Cake Box Holdings PLC, down 7.3% at 266.50p, 12-month range 155.00p-356.00p. The eggless deserts maker notes movement in shares. It confirms that it has recently emailed customers in relation to a data breach experienced in 2020 as a result of which personal and financial information may potentially have been accessed. Cake Box says it has taken the appropriate steps to investigate the incident, repair the compromised systems, and identify those customers that may have been compromised. It also has further strengthened the security of its systems to prevent future breaches, it says. "The company confirms that the data breach is not expected to have a material financial impact and as per the announcement on 12 April 2021, full year results are expected to be in line with market expectations," Cake Box adds.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
11 Apr 2016 12:20

Midatech Pharma Announces Launch Of Zuplenz In US

Read more
6 Jan 2016 10:18

WINNERS & LOSERS SUMMARY: ARM Hit By iPhone Production Cut Report

Read more
6 Jan 2016 07:57

Midatech Pharma 2015 Revenue To Come In Ahead Of Expectations

Read more
4 Jan 2016 14:18

Midatech particle technology to be used in vaccines

(ShareCast News) - Midatech Pharma's proprietary technology received a boost on Monday, with the news it had signed a licensing agreement with a private British biotechnology company. The AIM-listed pharmaceutical company - focused on products in oncology and other therapeutic areas - reported it ha

Read more
4 Jan 2016 07:35

Midatech Pharma Signs Licensing Deal With Emergex Vaccines

Read more
18 Dec 2015 09:53

Midatech Pharma Agrees To Buy Zuplenz From Galena Biopharma

Read more
18 Dec 2015 09:39

BROKER RATINGS SUMMARY: UBS Initiates Restaurant Group At Buy

Read more
14 Dec 2015 08:28

Midatech Pharma Appoints Centurion Pharma For Q-Octreotide In Turkey

Read more
4 Dec 2015 09:33

BROKER RATINGS SUMMARY: Barclays Downgrades Whitbread To Equal Weight

Read more
19 Nov 2015 10:00

Midatech Pharma Files Supplemental Disclosure In Relation To DARA Buy

Read more
15 Sep 2015 08:42

BROKER RATINGS SUMMARY: UBS Initiates Legal & General With Sell

Read more
14 Sep 2015 08:08

Midatech Pharma Loss Widens On Acquisition Costs, Investment

Read more
13 Aug 2015 07:00

Midatech Signs Deal With Eye Disesases Company Ophthotech

Read more
23 Jul 2015 08:04

Midatech Pharma Begins Phase IIa Study For MSL-001

Read more
23 Jun 2015 14:57

DIRECTOR DEALINGS: Midatech Pharma Finance Director Buys 500 Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.